WNK2 and melanoma: The oncogenic driver mutations BRAF and NRAS, found in approximately 50% and 30% of melanomas, respectively, contribute to constitutive activation of mitogen activated protein kinase (MAPK) and PI3K pathway signaling, resulting in unabated cell growth, but rendering melanomas susceptible to inhibition of BRAF or its downstream target MEK [8, 9].